The data confirm that higher frequencies of leukemia-derived DC (DCleu) and (leukemia-specific) immune cells, particularly Tcm, Tβ7, Tgd and NK cells are associated with improved clinical outcomes, prolonged relapse-free survival and enhanced responses to induction therapy. This evidence concerns the gene ABCA1 and leukemia.